Fred Alger Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $220K | Sell |
1,671
-314
| -16% | -$41.7K | ﹤0.01% | 420 |
|
|
2025
Q4 | $282K | Sell |
1,985
-137
| -6% | -$19.8K | ﹤0.01% | 446 |
|
|
2025
Q3 | $298K | Buy |
2,122
+113
| +6% | +$15.3K | ﹤0.01% | 418 |
|
|
2025
Q2 | $253K | Sell |
2,009
-265
| -12% | -$30.4K | ﹤0.01% | 412 |
|
|
2025
Q1 | $252K | Buy |
+2,274
| New | +$288K | ﹤0.01% | 399 |
|
|
2024
Q1 | – | Sell |
-7,339
| Closed | -$967K | – | 480 |
|
|
2023
Q4 | $967K | Sell |
7,339
-82,599
| -92% | -$9.51M | 0.01% | 369 |
|
|
2023
Q3 | $10.1M | Buy |
+89,938
| New | +$9.47M | 0.06% | 179 |
|
|
2023
Q2 | – | Sell |
-176
| Closed | -$17.8K | – | 553 |
|
|
2023
Q1 | $17.8K | Sell |
176
-206,521
| -100% | -$21.5M | ﹤0.01% | 501 |
|
|
2022
Q4 | $24.7M | Buy |
206,697
+206,473
| +92,175% | +$24.2M | 0.13% | 152 |
|
|
2022
Q3 | $24K | Hold |
224
| – | – | ﹤0.01% | 489 |
|
|
2022
Q2 | $22K | Buy |
+224
| New | +$20.7K | ﹤0.01% | 477 |
|
|
2020
Q2 | – | Sell |
-7,775
| Closed | -$673K | – | 567 |
|
|
2020
Q1 | $673K | Sell |
7,775
-30,550
| -80% | -$2.99M | ﹤0.01% | 345 |
|
|
2019
Q4 | $4.12M | Buy |
38,325
+10,023
| +35% | +$1.05M | 0.02% | 245 |
|
|
2019
Q3 | $2.55M | Buy |
28,302
+4,208
| +17% | +$393K | 0.01% | 268 |
|
|
2019
Q2 | $2.03M | Sell |
24,094
-17,421
| -42% | -$1.43M | 0.01% | 294 |
|
|
2019
Q1 | $3.66M | Sell |
41,515
-4,323
| -9% | -$361K | 0.01% | 248 |
|
|
2018
Q4 | $3.27M | Sell |
45,838
-14,446
| -24% | -$1.38M | 0.02% | 253 |
|
|
2018
Q3 | $7.41M | Sell |
60,284
-1,253
| -2% | -$142K | 0.03% | 190 |
|
|
2018
Q2 | $6.04M | Buy |
61,537
+15,315
| +33% | +$1.37M | 0.03% | 201 |
|
|
2018
Q1 | $3.83M | Buy |
46,222
+8,492
| +23% | +$717K | 0.02% | 248 |
|
|
2017
Q4 | $2.93M | Buy |
37,730
+31,905
| +548% | +$2.18M | 0.01% | 261 |
|
|
2017
Q3 | $357K | Buy |
5,825
+5,431
| +1,378% | +$287K | ﹤0.01% | 366 |
|
|
2017
Q2 | $18K | Sell |
394
-17,000
| -98% | -$825K | ﹤0.01% | 460 |
|
|
2017
Q1 | $753K | Sell |
17,394
-32,489
| -65% | -$1.39M | ﹤0.01% | 340 |
|
|
2016
Q4 | $1.93M | Buy |
49,883
+5,749
| +13% | +$260K | 0.01% | 263 |
|
|
2016
Q3 | $2.23M | Buy |
44,134
+6,014
| +16% | +$300K | 0.01% | 253 |
|
|
2016
Q2 | $1.73M | Sell |
38,120
-51,598
| -58% | -$2.38M | 0.01% | 284 |
|
|
2016
Q1 | $3.55M | Sell |
89,718
-71,698
| -44% | -$2.85M | 0.02% | 287 |
|
|
2015
Q4 | $9.13M | Sell |
161,416
-14,352
| -8% | -$729K | 0.04% | 190 |
|
|
2015
Q3 | $6.99M | Sell |
175,768
-110,541
| -39% | -$5.34M | 0.04% | 237 |
|
|
2015
Q2 | $13.7M | Sell |
286,309
-103,461
| -27% | -$4.39M | 0.06% | 193 |
|
|
2015
Q1 | $15.5M | Sell |
389,770
-236,041
| -38% | -$8.44M | 0.07% | 210 |
|
|
2014
Q4 | $14M | Buy |
625,811
+29,981
| +5% | +$568K | 0.07% | 216 |
|
|
2014
Q3 | $9.34M | Buy |
+595,830
| New | +$8.9M | 0.05% | 266 |
|
|
2013
Q4 | – | Sell |
-1,521
| Closed | -$17K | – | 590 |
|
|
2013
Q3 | $17K | Buy |
+1,521
| New | +$20.9K | ﹤0.01% | 503 |
|
Other funds holding NBIX
VPM
VCM
Fred Alger Management's NBIX Position: Q1 2026 in Review
Fred Alger Management reduced its Neurocrine Biosciences (NBIX) stake by 16% in Q1 2026, selling an estimated $41.7K and leaving 1,671 shares worth $220K. The position accounts for ﹤0.01% of the portfolio, ranked #420.
Fred Alger Management first reported a position in NBIX in Q3 2013 and has held it in 35 quarters since. The position peaked at $24.7M in Q4 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Fred Alger Management held 1,671 shares of Neurocrine Biosciences worth $220K as of Q1 2026.
- Fred Alger Management sold 314 Neurocrine Biosciences shares in Q1 2026, an estimated $41.7K.
- Neurocrine Biosciences made up ﹤0.01% of Fred Alger Management's portfolio in Q1 2026, its #420 holding.
- Fred Alger Management first reported a position in Neurocrine Biosciences in Q3 2013 and has held it in 35 quarters since.
- Fred Alger Management's Neurocrine Biosciences position peaked at $24.7M in Q4 2022.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.